The overall picture of the Swiss biotech industry is quite positive. The Swiss Biotech Report recently published provides an analysis of the 2023 biotech funding as well as other key ratios and statistics: https://lnkd.in/dGSvh2d With Swiss Biotech Association https://lnkd.in/dAtS7hyU
Innosuisse’s Post
More Relevant Posts
-
The biotech funding market is highly competitive, but science that addresses unmet clinical needs and drives progress in key therapeutic areas is still receiving funding. However, the science alone isn’t guaranteed to beat the competition. Read investor insights and best practices to maximise your prospects of securing funding in part one of our two-part biotech funding whitepaper series. https://ow.ly/rQsk50RrQZl
-
-
The nation's premier measurement science lab unleashes innovation for American industries
Listen to my colleague Michael J. Tarlov describe the development of the National Institute of Standards and Technology (NIST) Biomanufacturing Program, which provides the #biopharmaceutical and #biotech sectors with measurements and reference materials for their processes and product quality assurance. https://lnkd.in/eV--AAij
-
Get a sneak peek of Merck's Viscosity Reduction Platform in MabDesign's newsletter! You'll learn everything you need to go from intravenous to subcutaneous.
[📢 #BioprocessWatch] Watch out ! MabDesign’s second BioprocessWatch edition of 2023 is here and it focuses on Analytical Tools in Bioprocessing. We would like to thank our sponsors and contributors, Clean Cells, Pierre Fabre Group, QUALITY ASSISTANCE S.A., bioMérieux, ABL Europe & Bio-Techne, ExcellGene SA, Sartorius Stedim Biotech and Merck We would also like to acknowledge our three editors in chief, Alain Beck from Pierre Fabre Group, Arnaud Delobel from QUALITY ASSISTANCE S.A. and Félix A MONTERO-JULIAN PhD from bioMérieux for their tremendous support and guidance for this unique edition. Download here: https://lnkd.in/ebuh8j8Y
-
-
It’s frustrating for your research that a wealth of public experimental data exists, without standardization and meaning. Check out our webinar to learn how to overcome this by leveraging the synergy between QIAGEN Biomedical Knowledge Base #BKB and QIAGEN OmicSoft Lands to fuel your drug discovery programs. #drugdiscovery #bioinformatics ➡️ https://lnkd.in/efYAqghX
-
-
Duration is the major driver of cost for clinical trials. Optimising your development timelines, including efficient engagement with regulators, can significantly benefit scare budget allocation. Get advice and insights from our biotech experts by downloading our biotech funding whitepaper series here: https://ow.ly/pS4y50RrYpV
-
-
Our Annual Biotech Symposium unites drug development professionals to discuss the nonclinical development of biotherapeutics including regulatory issues and innovative approaches to problem solving. This is about a month out, so register today! https://okt.to/PozcNF #drugdevelopment #biotech #biotechnology #celltherapy #drugdiscovery
Charles River Biotech Symposium
events.criver.com
-
Last chance to join our exclusive webinar series tailored for commercial and market access biotech professionals. Make sure to save your seat today to get insights! skp.link/2fz #BiotechWebinar #BiotechnologyIndustry #MarketAccess #SKEvent #SimonKucher #BetterGrowth
-
Learn more about Depixus at depixus.com
Depixus very much enjoyed #BostonDOT23! Our President & CEO, Gordon Hamilton, gave talk on “Magnetic force spectroscopy – a novel approach to Improve the hit-to-lead and lead optimization phases of RNA-targeted small-molecule drug discovery.” The talk received excellent engagement from the audience, as indicated by the sheer number of great questions at the end! Gordon Hamilton will also be delivering a webinar entitled 'Transforming RNA-targeted drug discovery with MAGNA', 10:30am EDT/4:30pm CEST on Wednesday 11th October. You can register at depixus.com/webinars @Cambridge HealthTech Institute #DrugDiscovery #BostonDOT23 #RNA#SmallMolecules #DrugTargets #Biotech #Spectroscopy
-
-
Since 1907, the Scientific Information Solution people of CAS have been building the platforms behind discovery, breakthrough, and innovation. SciFinder? That’s CAS. STN? That’s CAS. Those CAS numbers? You get the point.
CAS BioFinder saves you time, mitigates risks, and accelerates your drug discovery program. Working through the literature to find disease targets, plan structure-activity-relationship studies, and assess the potential for off-target interactions takes time and risks missing key information. With CAS BioFinder, you can quickly access the verified data you need along with predicted bioactivity values, all derived from the existing literature—ensuring confidence that you always have the most relevant results. Our expert scientists have combed through the literature and patents, extracted information relevant to drug discovery scientists, and connected related data points so that you can quickly answer your drug discovery questions. This commitment to manual curation by CAS experts means you can trust the quality of the insights you uncover. Leverage existing and predicted bioactivity, ligand, sequence, and biomarker data, all accessible from the streamlined CAS BioFinder user interface, to save time and accelerate your drug discovery program.
International Sales and Business Management | Transformational Change | Chemicals | Plastics | Information Technology
Exciting times at CAS, as we released our CAS BioFinder Discovery Platform, providing a centralized database and tool for drug discovery.
Empowering Innovation & Scientific Discoveries
cas.org
-
BCBN Feed: STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch https://lnkd.in/g5sSrkdC Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter. ... [...]
STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch
